Post hoc analysis of trials of subcutaneous infliximab maintenance in 525 patients with Crohn's disease or ulcerative colitis: anti-drug antibodies (about 64%) lowered drug levels but showed no significant difference in week 54 remission, persistence or safety.
Secondary analysisn = 525 patients
Colombel et al. Impact of Immunogenicity on Clinical Outcomes in Patients With Moderate-to-Severe Inflammatory Bowel Disease Receiving Subcutaneous Infliximab: A Post Hoc Analysis of the LIBERTY Trials